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INTRODUCTION {#s1}
============

Metastasis to the orbital cavity is an unusual event and believed to occur in approximately 2-3% of patients with systemic cancer. The incidence of metastasis to the orbital cavity varies from 1% to 13% of orbital tumors.^[@R1],[@R2]^ Patients who have small orbital lesions may remain asymptomatic. Poor general condition in patients with the widespread disease may mask the orbital symptoms leading to a low rate of referral to concerned specialists.^[@R3]^ The actual incidence of orbital metastasis is thought to be higher than that described in the literature and this discrepancy is because of improved treatment leading to an increase in the median survival of patients with cancer, which in turn increases the chances of development of metastatic lesions the orbit. Advances in the diagnostic methods led to the increased detection of lesions and an increased volume of medical literature on orbital metastasis has increased the awareness of these lesions.^[@R4]^

CASE REPORT {#s2}
===========

72-year-old male patient, with ECOG (Eastern Cooperative Oncology Group) performance status of 1, presented with progressive proptosis of the left eye with pain, weight loss, loss of appetite, and weakness since 3 months earlier. There was no history of trauma to the left eye, headache, vomiting, abnormal body movements, fever, and congestion or discharge from the eye. He was non-alcoholic, non-smoker, and non-diabetic. The patient had no history suggestive of any drug intake or alcohol consumption or jaundice in the past or any immune-compromised status and his family history was not contributory. On admission, his vitalsigns and temperature were within the normal range for his age. On examination left eye was proptosed with a mass in the upper, outer, and lateral aspect of the orbit, which was soft to firm in consistency, mild to moderately-tender, not fixed to the underlying tissue and not associated with any discharge from the local site. The size of the mass was around 5.5cm × 3.50 cm (figure. 1). On per abdominal examination, the liver margin was palpated 5 cm below the right costal margin in mid-clavicular line and there was no ascites.
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Complete blood count and renal functions were within normal limits. His liver function tests such asserum alanine aminotransferase (ALT), serum aspartate transaminase (AST), serum gamma-glutamyltranspeptidase (GGT), total protein, albumin level, lactate dehydrogenase (LDH), ferritin, and prothrombin time (PT) levels were within the normal range. Serum alpha-fetoprotein \[AFP\] was 1.69 ng/mL. The patient's serology was positive for hepatitis B surface antigen and hepatitis B virus-DNA. His serum was negative for hepatitis C virus (anti-HCV) and PCR for HCV-RNA for hepatitis C, anti-mitochondrial antibody and carcinoembryonic antigen (CEA). Computed tomography (CT) of head and neck revealed heterogeneously enhancing irregular extraconal mass lesion measuring approximately 5.7 × 4.7cm in the superolateral aspect of the left orbit. It was breaching the lateral wall and roof of the orbit and extending into subcutaneous scalp tissue layers of the left frontal region. It was causing mass effect on eyeball resulting in the proptosis of the left eyeball and invading the left-sided extraconal muscles, left lateral rectus and superior oblique muscles ([figure 2](#F2){ref-type="fig"}). Triphasic abdominal CT showed hepatomegaly withmultiple heterogeneously enhancing lesions in both lobes of the liver, the largest being 83.8 × 84.6 mm ([figure 3](#F3){ref-type="fig"}). Cytology smears of fine needle aspiration from proptotic lesion and liver mass showed clusters and sheets of round to polyhedral cells, which were scattered individually with enlarged, hyperchromatic nuclei, prominent nucleoli, and moderately abundant eosinophilic cytoplasm. Anisonucleosis was also seen. Some cells showed intranuclear inclusions. Many atypical stripped nuclei were seen. Scattered cells with large, bizarre nuclei were also seen ([figure 4](#F4){ref-type="fig"}). On further examination tumor cells had strong immunoreactivity for hepatocyte paraffin 1 (HepPar 1) and CD 10 but negative for TTF-1 (thyroid transcription factor 1), CEA (carcinoembryonic antigen), ALK-1(Activin Receptor- like Kinase), LCA(Leukocyte common antigen), vimentin, S-100, and chromogranin. The results of immunohistochemistry were thus consistent with a diagnosis of metastatic hepatocellular carcinoma (HCC).
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Sorafenib 400 mg twice a day was started for the patient and he is under treatment until this date. After one month of starting the sorafenib there was a significant improvement in the performance status and symptoms in the form of increased appetite, increased weight, and subjective wellbeing of the patient. There was also a decrease in the size of the liver mass and the orbital mass. Imaging studies were suggestive of a decrease in the size of the intraorbitaland liver masses. The patient is under regular evaluation in our center for clinical signs and signs of liver decompensation. Imaging studies with two monthly dynamic CT of the abdomen is done for any progression of the disease since 7 months age.

DISCUSSION {#s3}
==========

Worldwide HCC is the seventh most common cancer and around 626,000 new patients are diagnosed globally each year; among them, 50% are in China, with a mortality rate of 94%.^[@R5]^ HCC is associated with alcoholic liver diseases, infections like hepatitis C virus, and hepatitis B virus, autoimmune hepatitis, steatohepatitis, primary biliary and sclerosing cholangitis, intake of aflatoxin-contaminated food, diabetes, and obesity.^[@R6]^

One study from Australia showed metastasis to the orbit and malignant melanoma (20%) followed by prostatic carcinoma (13%), while in another study done in the People's Republic of China, the most common primary cancers that metastasized to the orbit in the descending order were nasopharyngeal carcinoma (30.3%), lung cancer (8.7%), liver cancer (6.5%), and breast cancer (4.35%).^[@R7],[@R8]^

Oncologists should have knowledge regarding, primary neoplasms and metastatic tumors to the orbit, which causes proptosis and pain. Primary orbital tumors associated with painful proptosis are adenoid cystic carcinoma of the lacrimal gland, malignant peripheral nerve sheath tumor (malignant schwannoma), and direct orbital invasion by neurotrophic squamous cell carcinoma from the skin of the eyelid and periorbital region. Among the metastatic lesions to the orbit, one must include prostatic adenocarcinoma, HCC, breast cancer, Langerhans cell histiocytosis, and lung carcinoma.

HCC is a type of tumor with a rich blood supply. Vascular endothelial growth factor (VEGF), as the most important vascular growth factor, is significantly overexpressed in patients with HCC compared with patients with cirrhosis, hepatitis, and so forth. For patients with and without bone metastasis, a statistical difference is also observed in the expression level of VEGF. This factor may facilitate the formation of a metastatic niche and subsequent mass.^[@R9]^

Goldberg and Rootman described the features of orbital metastasis as^[@R4],[@R10]^:

1.  Infiltrative with prominent motility restriction and sometimes enophthalmos (most common);

2.  Mass effect with proptosis and/or globe displacement;

3.  Inflammatory; and

4.  Functional.

CT and magnetic resonance imaging (MRI) are the principal means for evaluating orbital lesions. The definitive diagnosis of an orbital metastasis requires tissue evaluation by a pathologist. Fine needle aspiration has been advocated as a good diagnostic modality.^[@R11]^

The preferred treatment of metastatic or inoperable HCC includes sorafenib and lenvatinib. Other subsequent lines of treatment if the disease progresses on preferred treatments include regorafenib, cabozantinib, ramucirumab (if AFP \> 400 ng/ml only), sorafenib after first-line lenvatinib, and immunotherapeutic agents such as nivolumab and pembrolizumab.
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